Wang X, Zhang X, Men T, Wang Y, Gao H, Meng Y, Wang J
Taishan Medical University, Taian 271016, Shandong Province, People's Republic of China; Department of Urinary Surgery, Shandong Province Qianfoshan Hospital, Shandong University, Jinan, Shandong Province, People's Republic of China.
Department of Urinary Surgery, Shandong Province Qianfoshan Hospital, Shandong University, Jinan, Shandong Province, People's Republic of China.
Transplant Proc. 2018 Jan-Feb;50(1):48-52. doi: 10.1016/j.transproceed.2017.12.006.
The increase in the prevalence of end-stage renal disease in developed countries and the shortage of deceased donors have made it necessary to increase the graft pool by means of several strategies, such as living donation, non-heart-beating organ donors, and expanded-criteria donors. This study aimed to assess the short-term outcomes of donor kidneys with small (≤3.5 cm) renal cell carcinoma (sRCC) and to evaluate the possibility of using marginal kidneys in renal transplantation.
Patients undergoing nephrectomy for sRCC who agreed to donate their kidneys were enrolled in the study. Seven dialysis patients aged 27-54 years agreed to undergo transplantation with sRCC kidneys. All of the transplantations were performed in Shandong Province Qianfoshan Hospital from May 2012 to March 2017. The function of transplanted kidneys was evaluated after surgery by testing and comparing parameters such as creatinine clearance rate, delayed graft function, and tumor recurrence.
The graft function of the transplanted kidneys was recovered to normal in all of the 7 patients who received sRCC kidneys. The latest serum creatinine levels before publication ranged from 59 to 102 μmol/L in the 7 recipients (normal range of serum creatinine: men, 54-106 μmol/L; women, 44-97 μmol/L). No tumor recurrence was noted 31-58 months after surgery in the recipients.
According to short-term follow up (3-5 years), kidney transplantation in selected patients can be considered for kidneys having small incidental tumors. The use of marginal organs, such as those with sRCC, can increase the donor pool for kidney transplantation.
发达国家终末期肾病患病率的增加以及已故供体的短缺,使得有必要通过多种策略增加移植肾库,如活体捐赠、非心脏跳动器官捐赠者和扩大标准捐赠者。本研究旨在评估患有小(≤3.5 cm)肾细胞癌(sRCC)的供体肾的短期结局,并评估在肾移植中使用边缘肾的可能性。
同意捐赠肾脏的因sRCC接受肾切除术的患者纳入本研究。7名年龄在27 - 54岁的透析患者同意接受sRCC肾移植。所有移植手术均于2012年5月至2017年3月在山东省千佛山医院进行。术后通过检测和比较肌酐清除率、移植肾功能延迟恢复和肿瘤复发等参数评估移植肾的功能。
接受sRCC肾移植手术的7例患者移植肾功能均恢复正常。在发表前,7例受者的最新血清肌酐水平为59至102 μmol/L(血清肌酐正常范围:男性,54 - 106 μmol/L;女性,44 - 97 μmol/L)。术后31 - 58个月受者未发现肿瘤复发。
根据短期随访(3 - 5年),对于有小的偶然肿瘤的肾脏,可考虑为选定患者进行肾移植。使用边缘器官,如患有sRCC的器官,可增加肾移植的供体库。